Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsKatrin Preller
Assistant Professor Adjunct, PsychiatryAbout
Research
Publications
2025
The emotional architecture of the psychedelic brain
Moujaes F, Rieser N, Belinger L, Herdener M, Zahid Z, Preller K. The emotional architecture of the psychedelic brain. Trends In Cognitive Sciences 2025 PMID: 40830011, DOI: 10.1016/j.tics.2025.07.006.Peer-Reviewed Original ResearchEffects of psychedelicsImpact of psychedelicsEmotional processingMood disordersEmotional empathySerotonergic psychedelicsPsychiatric conditionsEmotion management strategiesPsychedelicsNeuroplastic changesMoodEmotional statesTemporal dynamicsEmotionsMechanism of actionComplex pictureTherapeutic impactEmotional architectureEmpathyDisordersBrainTherapeutic potentialClinical studiesTreatment approaches and efficacy in psychedelic-induced psychosis: A systematic review
Sulstarova A, Scheuerlein L, Monari S, Seragnoli F, Gabriel T, Preller K, Böge K, Sentissi O, Kaiser S, Solmi M, Kirschner M, Sabé M. Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review. Asian Journal Of Psychiatry 2025, 110: 104604. PMID: 40614615, DOI: 10.1016/j.ajp.2025.104604.Peer-Reviewed Original ResearchConceptsFirst-generation antipsychoticsSecond-generation antipsychoticsElectroconvulsive therapySchizophrenia spectrum disordersRisk of psychosisSecond-generation agentsCase seriesCase reportFollow-upBipolar disorderAntipsychoticsMinority of usersPsychosisSpectrum disorderAverage patient agePrimary substanceFollow-up dataSystematic reviewInterpretation of findingsComprehensive follow-upTreatment approachesSecond-generationPatient ageProspective studyTreatment optionsA Consensus Taxonomy of Altered (Nonordinary) States of Consciousness: Bringing Order to Disarray
Cardeña E, Berkovich-Ohana A, Valli K, Barttfeld P, Gomez-Marin A, Greyson B, Kumar V, Laureys S, Luhrmann T, Newberg A, Preller K, Putnam F, Tagliazucchi E, Walsh R, Carter O, Yaden D. A Consensus Taxonomy of Altered (Nonordinary) States of Consciousness: Bringing Order to Disarray. Psychology Of Consciousness Theory Research And Practice 2025 DOI: 10.1037/cns0000431.Peer-Reviewed Original ResearchNeurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans
Berkovitch L, Fauvel B, Preller K, Gaillard R. Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans. Neuroscience & Biobehavioral Reviews 2025, 175: 106239. PMID: 40456393, DOI: 10.1016/j.neubiorev.2025.106239.Peer-Reviewed Original ResearchConceptsEffects of psilocybinPsilocybin effectsNeuroimaging studiesBrain changesNeuroimaging techniquesTherapeutic effects of psilocybinTreat various psychiatric disordersFunctional brain changesSamples of healthy volunteersSerotonergic compoundsEmotional processingNeurobiological mechanismsMode networkPsychiatric disordersCognitive tasksPsychoactive effectsBrain activityNeuroimaging dataPsilocybinSelf-experienceAssociated with acute alterationsSocial functioningTherapeutic effectBrainNeuronal networksPictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments
Pouyan N, Aday J, Harte S, Kaplan C, Williams D, Glynos N, Herberholz M, Kruger D, Barron J, Mashour G, Clauw D, Preller K, Schrepf A, Boehnke K. Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments. Journal Of Psychopharmacology 2025, 39: 489-498. PMID: 40323119, DOI: 10.1177/02698811251330763.Peer-Reviewed Original ResearchConceptsNaturalistic psychedelic usePsychedelic useSymptom changeSymptom improvementAssociated with symptom improvementEffects of psychedelicsPosttraumatic stress disorderIndividual perceptions of selfPerceptions of selfPRISM scoreRepresentations of illnessPsychedelic treatmentStress disorderGlobal ImpressionPsychedelic experiencePictorial representationPictorial Representation of IllnessRetrospective reportsSelf-PerceptionReduced identificationChange scoresRetrospectively assessed changesPGIC scoresPatient Global ImpressionConvenience sample481. Resting-State Perfusion and Executive Control Task Performance in Psychosis Spectrum Disorder
Cail C, Rahmati M, Fonteneau C, Zharyy C, Forselius-Bielen K, Beri E, Miller E, Santamauro N, Anticevic A, Cortes-Briones J, Proulx E, Preller K, Cho Y. 481. Resting-State Perfusion and Executive Control Task Performance in Psychosis Spectrum Disorder. Biological Psychiatry 2025, 97: s295-s296. DOI: 10.1016/j.biopsych.2025.02.719.Peer-Reviewed Original Research533. Bold Signal Can Capture Individual Variability in Spatial Working Memory Deficits Induced by Ketamine
Rahmati M, Moujaes F, Purg N, Fonteneau C, Santamauro N, Tamayo Z, Repovs G, Preller K, Anticevic A, Fineberg S, Murray J, Krystal J, Cho Y. 533. Bold Signal Can Capture Individual Variability in Spatial Working Memory Deficits Induced by Ketamine. Biological Psychiatry 2025, 97: s317. DOI: 10.1016/j.biopsych.2025.02.772.Peer-Reviewed Original Research595. Psilocybin-Assisted Therapy for Relapse Prevention in Alcohol Use Disorder: A RCT
Rieser N, Bitar R, Simon H, Rossgoderer C, Gubser L, Thévenaz M, Kreis Y, von Rotz R, Nordt C, Moujaes F, Engeli E, Ort A, Seifritz E, Vollenweider F, Preller K. 595. Psilocybin-Assisted Therapy for Relapse Prevention in Alcohol Use Disorder: A RCT. Biological Psychiatry 2025, 97: s343-s344. DOI: 10.1016/j.biopsych.2025.02.834.Peer-Reviewed Original Research324. Effects of Hallucinogenic Drug Use on Neurocognitive Function and Mental Health: An International Online Study
Saelens J, Stadler F, Rieser N, Greenwald M, Ballard E, Park L, Preller K, Zarate C, Kraus C. 324. Effects of Hallucinogenic Drug Use on Neurocognitive Function and Mental Health: An International Online Study. Biological Psychiatry 2025, 97: s229. DOI: 10.1016/j.biopsych.2025.02.562.Peer-Reviewed Original ResearchPsilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
Rieser N, Bitar R, Halm S, Rossgoderer C, Gubser L, Thévenaz M, Kreis Y, von Rotz R, Nordt C, Visentini M, Moujaes F, Engeli E, Ort A, Seifritz E, Vollenweider F, Herdener M, Preller K. Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. EClinicalMedicine 2025, 82: 103149. PMID: 40144690, PMCID: PMC11937691, DOI: 10.1016/j.eclinm.2025.103149.Peer-Reviewed Original ResearchAlcohol use disorderDose of psilocybinAlcohol use disorder patientsAlcohol useWithdrawal treatmentUse disorderOral doses of psilocybinTherapeutic effects of psilocybinSingle dose of psilocybinEffects of psilocybinInpatient withdrawal treatmentPsilocybin-assisted therapyDaily alcohol useReducing relapse ratesRelapse ratePsilocybin groupPsychotherapy sessionsReduce cravingFollow-upAbstinence durationRelapse preventionPlacebo groupPsilocybinPrevent relapsePsychotherapy